Results 101 to 110 of about 79,764 (263)

Electroconvulsive Therapy and Time to Psychiatric Readmission in Schizophrenia

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction There is evidence that electroconvulsive therapy (ECT) can augment the effects of antipsychotics in schizophrenia. However, there is limited evidence from Western populations on whether ECT reduces the risk of relapse compared to non‐ECT treatment in schizophrenia.
Linnea Stenmark, Mussie Msghina, Axel Nordenskjöld   +2 more
wiley   +1 more source

Does the Loss of Autobiographical Memories Contribute to the Therapeutic Effect of Electroconvulsive Therapy?

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Objective For decades, a persistent claim has been that autobiographical memory loss after electroconvulsive therapy (ECT) for depression might actually contribute to ECT efficacy by reducing or even eliminating autobiographical memories. To test this claim, the primary aim of this study is to examine the association between autobiographical ...
Mike van Kessel, Joris van der Vlugt‐Molenaar, Isidoor O. Bergfeld, Eric van Exel, Jaap Murre, Jasmien Obbels, Pascal Sienaert, Kristof Vansteelandt, Esmée Verwijk   +8 more
wiley   +1 more source

Clobazam to preserve meaningful engagement in prolonged disorder of consciousness with concurrent seizure disorder

PM&R, EarlyView.
Tatiana Bernstein, Zachary Miklja, Tiffany Wood, Joshua Startup   +3 more
wiley   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source

Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system

Drug Design, Development and Therapy, 2019
Nora Freyer,1 Fanny Knöspel,1 Georg Damm,2 Selina Greuel,1 Christin Schneider,1 Daniel Seehofer,2 Thomas Stöhr,3 Karl-Uwe Petersen,3 Katrin Zeilinger1 1Berlin Brandenburg Center for Regenerative Therapies (BCRT), Charité &ndash ...
Freyer N, Knöspel F, Damm G, Greuel S, Schneider C, Seehofer D, Stöhr T, Petersen KU, Zeilinger K   +8 more
doaj  

Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5‐Year Follow‐Up

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction We aimed to investigate the risks of all‐cause and cause‐specific mortality associated with dose‐dependent benzodiazepine and Z‐drug (BZDR) use in the Finnish population initiating new BZDR use with five‐year follow‐up. Methods Study subjects were included if BZDR use had started in 2006 with no BZDR dispensing during the ...
Hanna Särkilä, Heidi Taipale, Antti Tanskanen, Tero Taiminen, Reijo Sund, Terhi Kurko, Jarmo Hietala, Solja Niemelä   +7 more
wiley   +1 more source

Long-Term Trends in Prescribing of Etizolam for Hypnotic Use in a Japanese University Hospital. [PDF]

Hum Psychopharmacol
Nakao M, Morohoshi H, Kurata Y, Nakamura A.   +3 more
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study. [PDF]

PLoS Med
Bozinoff N, Hauck TS, Kleinman RA, Sloan ME, Sproule BA, Vigod SN, Wyman J, Pequeno P, Gomes T.   +8 more
europepmc   +1 more source